Eterna Therapeutics Inc (ERNA) Stock Price, Quote & News

Company Profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The compa...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 582 1199

Website: www.ernexatx.com

Address:

1035 Cambridge Street, Suite 18A, Cambridge, United States

Russell007xx Nov. 12 at 8:12 PM

$ERNA $CYPH next

0 · Reply

ProfitGainer Nov. 10 at 11:57 PM

$ERNA I bought the dip. It's going to run soon. Short fee is over 300% and no more shares to short. Short squeeze will be epic.

0 · Reply

Atcl Nov. 10 at 2:26 PM

$ERNA Amazing- lets see- GLTA

0 · Reply

Stock_Catcher Nov. 10 at 1:35 PM

$ERNA Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

0 · Reply

Runner_ Nov. 10 at 4:09 AM

$ERNA

0 · Reply

JerrySluder318 Nov. 7 at 4:37 PM

$ERNA maintains steady volume amid innovation sector momentum. AITX continues executing with precision, turning pilot programs into profitable long-term contracts.

0 · Reply

Atcl Nov. 7 at 3:22 PM

$BBD.B.TSX Bomb guys, Check out $ERNA - I gave you'll $CLS when at 80- today its around 350 - hate to cross post, but just helping, GLTA

1 · Reply

Atcl Nov. 7 at 3:06 PM

$OPEN Guys at OPEN check out $ERNA - next week could blow up- lets see, anyways- GLTA https://www.youtube.com/watch?v=Fl1kRLZwpDc

0 · Reply

VirtualInvestor Nov. 6 at 3:30 PM

$ERNA CEO, Sanjeev Luther, joined our #WhatThisMeans to discuss the recent #partnership with Cellipont to help advance its cell therapy program for ovarian cancer into clinical trials. https://youtu.be/Fl1kRLZwpDc?si=l18UbjduhdghT0G-

0 · Reply

VirtualInvestor Nov. 6 at 3:29 PM

$ERNA Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform https://www.globenewswire.com/news-release/2025/11/06/3182716/0/en/Ernexa-Therapeutics-Showcases-Strategic-Partnership-with-Cellipont-Bioservices-to-Advance-Toward-First-in-Human-Trials-on-Virtual-Investor-What-This-Means-Platform.html

0 · Reply

Ernexa Therapeutics to Present at Oxford Global's Cell 2025

Nov 10, 2025, 8:35 AM EST - 4 days ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

Nov 6, 2025, 9:15 AM EST - 8 days ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Oct 29, 2025, 8:33 AM EDT - 16 days ago

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Oct 1, 2025, 8:30 AM EDT - 6 weeks ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

Sep 29, 2025, 8:30 AM EDT - 6 weeks ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

Sep 17, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Sep 10, 2025, 8:30 AM EDT - 2 months ago

Ernexa Therapeutics Provides Update on Operational Excellence and Performance

Sep 3, 2025, 9:30 AM EDT - 2 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

Jul 9, 2025, 8:30 AM EDT - 4 months ago

Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 25, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Jun 24, 2025, 8:30 AM EDT - 5 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Jun 10, 2025, 9:30 AM EDT - 5 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

May 28, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

May 14, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

May 8, 2025, 8:30 AM EDT - 6 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 29, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Apr 22, 2025, 8:30 AM EDT - 7 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

Apr 3, 2025, 8:55 AM EDT - 8 months ago

Ernexa Therapeutics Closes New Funding Round

Feb 26, 2025, 8:30 AM EST - 9 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Jan 14, 2025, 8:30 AM EST - 10 months ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Jan 9, 2025, 7:30 AM EST - 11 months ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Nov 14, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

May 10, 2024, 8:00 AM EDT - 1 year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 8, 2024, 9:31 AM EDT - 1 year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Feb 20, 2024, 8:30 AM EST - 1 year ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Jan 3, 2024, 4:15 PM EST - 2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Dec 20, 2023, 4:15 PM EST - 2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Dec 14, 2023, 6:56 PM EST - 2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Nov 1, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors

May 24, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel

May 17, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 4, 2023, 8:30 AM EDT - 2 years ago

Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023, 7:30 AM EDT - 2 years ago

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

Mar 20, 2023, 4:10 PM EDT - 2 years ago

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Feb 22, 2023, 8:00 AM EST - 2 years ago

Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Jan 4, 2023, 8:30 AM EST - 3 years ago

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

Dec 20, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics

Nov 1, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Oct 18, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

Oct 17, 2022, 8:30 AM EDT - 3 years ago

Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics

Russell007xx Nov. 12 at 8:12 PM

$ERNA $CYPH next

0 · Reply

ProfitGainer Nov. 10 at 11:57 PM

$ERNA I bought the dip. It's going to run soon. Short fee is over 300% and no more shares to short. Short squeeze will be epic.

0 · Reply

Atcl Nov. 10 at 2:26 PM

$ERNA Amazing- lets see- GLTA

0 · Reply

Stock_Catcher Nov. 10 at 1:35 PM

$ERNA Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

0 · Reply

Runner_ Nov. 10 at 4:09 AM

$ERNA

0 · Reply

JerrySluder318 Nov. 7 at 4:37 PM

$ERNA maintains steady volume amid innovation sector momentum. AITX continues executing with precision, turning pilot programs into profitable long-term contracts.

0 · Reply

Atcl Nov. 7 at 3:22 PM

$BBD.B.TSX Bomb guys, Check out $ERNA - I gave you'll $CLS when at 80- today its around 350 - hate to cross post, but just helping, GLTA

1 · Reply

Atcl Nov. 7 at 3:06 PM

$OPEN Guys at OPEN check out $ERNA - next week could blow up- lets see, anyways- GLTA https://www.youtube.com/watch?v=Fl1kRLZwpDc

0 · Reply

VirtualInvestor Nov. 6 at 3:30 PM

0 · Reply

VirtualInvestor Nov. 6 at 3:29 PM

0 · Reply

JeanBets Nov. 6 at 2:18 PM

$ERNA 🦍⭐️💰

0 · Reply

Stock_Catcher Nov. 6 at 2:15 PM

$ERNA Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

0 · Reply